Eton Pharmaceuticals Acquires US Rights to Neonatal Diabetes Drug Amglidia-February 2024-www.financetom.com

Eton Pharmaceuticals Acquires US Rights to Neonatal Diabetes Drug Amglidia

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Eton Pharmaceuticals Acquires US Rights to Neonatal Diabetes Drug Amglidia

Nov 25, 2024 5:34 AM

08:29 AM EST, 11/25/2024 (MT Newswires) -- Eton Pharmaceuticals ( ETON ) said Monday it has acquired US rights to Amglidia oral suspension for neonatal diabetes mellitus from French biotech company AMMTeK.

The drug is approved in Europe and was granted orphan drug designation by the US Food and Drug Administration, Eton said.

Eton said it plans to meet with the FDA in Q1 2025 and aims to submit a new drug application for Amglidia in 2026.

Previous page： Goldman CEO Solomon says job cuts are coming next month Next page： Mukesh Ambani completes 20 years at the helm of Reliance — Full transcript of his speech at Reliance Family Day

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Goldman CEO Solomon says job cuts are coming next month

Dec 29, 2022

Goldman is on track to post about $48 billion in annual revenue, its second-best performance behind only last year’s record. An expensive foray into consumer banking and the subsequent retreat along with spending on technology and integrating operations have contributed to the cost bleed this year.

Mukesh Ambani completes 20 years at the helm of Reliance — Full transcript of his speech at Reliance Family Day

Dec 29, 2022

In his address to employees, Reliance Industries' Chairman Mukesh Ambani laid out his expectations from each of the conglomerates' businesses. He wants Jio to now provide unique solutions to the world, Reliance Retail to deliver significant benefits to all stakeholders, integration of media and entertainment with digital to reinvent the industry and the new energy business to transform the world.

Survival Technologies files draft papers with Sebi to raise ₹1,000 crore

Dec 29, 2022

The IPO comprises a fresh issue of equity shares aggregating to up to Rs 200 crore, and an Offer For Sale (OFS) aggregating to up to Rs 800 crore by its promoters and promoter group shareholders, according to its Draft Red Herring Prospectus (DRHP).

Mukesh Ambani sets goals for Reliance as he cites Messi to explain leadership

Dec 29, 2022

The end of 2022 is when Reliance will have crossed the half-way mark of its Golden Decade. In five years from now, Reliance will complete its fifty years. The journey ahead is going to be far more exciting, more rewarding, but also more challenging.